<DOC>
	<DOCNO>NCT02446561</DOCNO>
	<brief_summary>To determine whether three new oral formulation strong pain killer release drug body similar pattern already market reference capsule formulation without food</brief_summary>
	<brief_title>A Study Whether 3 New Oral Formulations Strong Pain Killer Release Same Amount Drug Into Body Marketed Medication</brief_title>
	<detailed_description>Comparisons make three new oral formulation exist market reference capsule formulation determine whether release rate product similar equivalent fed fast state . Determination measurement drug concentration blood serial collection time point pre-dose 72 hour post-dose , follow administration single oral dose . Pharmacokinetics parameter AUC Cmax primary endpoint</detailed_description>
	<criteria>1 . Provide write informed consent . 2 . Healthy male female subject age 18 55 inclusive . 3 . Female subject child bear potential must willing use two highly effective method contraception throughout study , one must include barrier method . 4 . Female subject postmenopausal ( define spontaneous amenorrhea least year ) permanently sterilise ( e.g . tubal occlusion , hysterectomy , bilateral salpingectomy ) . These subject require use contraception . 5 . Male subject must willing use contraception partner throughout study 30 day completion study agree inform Investigator partner become pregnant time . 6 . Body weight range 55 100 kg BMI ≥ 18.5 ≤ 30.0 . 7 . Healthy free significant abnormal finding determine medical history , physical examination , vital sign , laboratory test ECG . 8 . Willing eat food supply throughout study . 9 . The subject 's primary care physician confirm within last 12 month first dose nothing medical history would preclude enrolment clinical study 1 . Any history drug alcohol abuse . 2 . Any history condition might interfere drug absorption , distribution , metabolism excretion . 3 . Use opioid opioid antagonistcontaining medication past 30 day . 4 . Any history frequent nausea vomit regardless etiology . 5 . Any history seizures symptomatic head trauma . 6 . Any history paralytic ileus , respiratory depression , hypoxia elevate carbon dioxide level blood . 7 . Participation clinical drug study 90 day precede initial dose study . 8 . Subjects must participate pilot phase definitive phase study , one Cohort . 9 . Any significant illness 4 week precede entry study . 10 . Use medication include vitamin , herbal and/or mineral supplement 7 day precede initial dose course study ( exception continue use HRT contraceptive ) . 11 . Refusal abstain food 8 hour precede 4 hour follow study drug administration , abstain food contain poppy seed 48 hour precede entirely confinement , abstain caffeine xanthine contain food beverage grapefruit juice within 48 hour IMP administration duration study confinement last study PK sample take study period . 12 . Weekly alcohol intake exceed equivalent 14 units/week female 21 units/week male . ( 1 unit = ½ pint beer , 25 mL 40 % spirit 125 mL glass wine ) . 13 . Consumption alcoholic beverage within 48 hour study drug administration , refusal abstain alcohol duration study confinement least 48 hour last naltrexone dose study period . 14 . History smoking within 45 day study drug administration refusal abstain smoking study . 15 . Blood blood product donate within 90 day prior study drug administration time study , except require protocol . 16 . Positive result urine drug screen , alcohol test , pregnancy test , HBsAg , Hepatitis C antibody , HIV test . 17 . Refusal allow primary care physician inform participation trial . 18 . Failure satisfy Investigator fitness participate reason .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Healthy Volunteer</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>